DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Biodiesel Exhaust, Acute Vascular and Endothelial Responses

Information source: University of Edinburgh
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Healthy

Intervention: Forearm venous occlusion plethysmography study (Other)

Phase: N/A

Status: Completed

Sponsored by: University of Edinburgh

Official(s) and/or principal investigator(s):
Jenny A Bosson Damewood, MD PhD, Principal Investigator, Affiliation: Umeå University

Summary

Exposure to particulate air pollution has been shown to increase cardiovascular mortality and morbidity, and in previous controlled exposure studies has been shown to have acute cardiovascular and respiratory effects. The last decade has seen an unprecedented drive towards finding a bioeconomical and renewable source of fuel in order to reduce our dependence on fossil fuels. Although both biodiesel and bioethanol have emerged as contenders for future fuels, biodiesel remains as the strongest contender within European markets. In 2007 researchers at the EPA released a commentary, which concluded that the assumed correlation between the chemical composition of biodiesel exhaust and a reduction in health effects was only hypothetical. They suggested that there was a clear need for the study of health effects in humans regarding biofuel exhaust. In this project the investigators aim to investigate the cardiovascular, respiratory and inflammatory responses to biofuel exhaust exposure in healthy volunteers.

Clinical Details

Official title: Inhalation of Dilute Biodiesel Exhaust: Acute Vascular and Endothelial Responses

Study design: Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science

Primary outcome: Vascular vasomotor and fibrinolytic function

Secondary outcome:

Respiratory function tests

Inflammatory markers

Central arterial stiffness

Eligibility

Minimum age: 20 Years. Maximum age: 55 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- 20 healthy, non-smoking subjects, age 20-55 year old, both genders.

All subjects undergo a general health examination and are required to have: Normal clinical examination Normal EKG Normal routine blood tests Normal lung function Exclusion Criteria:

- Cardiovascular disease

- Diabetes Mellitus

- Asthma and/or allergy

- Respiratory infection within 3 weeks of the study

- Antioxidant- and/or vitamin supplementation within 2 weeks prior to, as well as

during the course of the study. (incl vitamin C, Acetylcysteine)

- Female subjects will take a urinary pregnancy test before each exposure and will be

excluded if this is positive.

Locations and Contacts

Umeå University Hospital, Umeå 901 85, Sweden
Additional Information

Starting date: April 2011
Last updated: November 30, 2011

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017